The funding highlights how service robotics is shifting from niche deployments to scaled commercial use across global markets
Updated
April 24, 2026 2:26 PM
An autonomous service robot with a cat face design standing inside a McDonalds restaurant. PHOTO: ADOBE STOCK
Pudu Robotics, a Shenzhen-based startup building robots for commercial environments, has raised nearly US$150 million in a new funding round, pushing its valuation past US$1.5 billion. The raise brings the company’s total funding to more than US$300 million.
The company focuses on service robotics across sectors such as delivery, cleaning and industrial logistics. Its systems are used in places like retail stores, warehouses and public venues where routine tasks can be automated. Over time, Pudu has expanded from single-purpose machines to a broader portfolio that combines hardware with AI-driven navigation and coordination.
The funding is expected to support several areas of growth. These include further development of its AI systems, expansion of its product range and continued international rollout. The company also plans to invest in manufacturing and supply chain capacity, suggesting a focus on scaling production alongside demand.
Pudu’s recent growth provides some context for the raise. The company reported a doubling of revenue by 2025, with its cleaning robots now accounting for the majority of its business. Its industrial delivery robots have also seen early traction, with thousands of units deployed within a year of launch.
Its products are already in use with large global retailers including Carrefour, Walmart and EDEKA. Industry estimates place Pudu among the largest players in commercial service robotics, with a leading share of the global market.
Technically, the company develops much of its core stack in-house, including navigation systems, multi-robot coordination software and motion control. This allows its robots to operate in complex real-world environments where multiple machines need to move and work together.
“This financial milestone is a powerful confirmation of Pudu’s industry leadership, the strength of its products and technology, its global brand, and its commercial infrastructure. With the support of our strategic investors and industry partners, Pudu will continue to push the boundaries of embedded AI and business service robotics. We remain committed to innovating with an inventor’s spirit and leveraging a global vision to accelerate robot adoption, thereby elevating the industry to new heights in the global value chain”. said Felix Zhang, founder and CEO of Pudu Robotics.
The funding round points to a broader shift in the sector. As service robotics moves from pilot deployments to wider adoption, companies are increasingly being judged on their ability to scale production and operate across markets, not just on the novelty of their technology.
Keep Reading
A new approach examines how individual cells respond to drugs, aiming to identify risks earlier in development.
Updated
April 15, 2026 6:01 PM
Close up of a capsule blister pack. PHOTO: UNSPLASH
DeepCyte, a startup in the drug development space, is focusing on a long-standing problem: why drugs that appear safe in early testing still fail in clinical trials or are withdrawn later due to toxicity. DeepCyte has launched with US$1.5 million in seed funding to build tools that detect and explain the harmful effects of drugs at much earlier stages.
The startup’s approach focuses on how individual cells respond to a drug. Instead of analysing cells in bulk, it studies them one by one. This helps capture differences in how cells react, which are often missed in traditional testing methods.
Drug toxicity remains one of the main reasons for failure in drug development. Methods such as animal testing and bulk cell analysis do not always reflect how human cells behave. This gap has pushed the industry to look for more reliable and human-relevant ways to test drug safety.
DeepCyte combines cell-level data with artificial intelligence. Its platform, MetaCore, studies what is happening inside individual cells by capturing detailed molecular information. This data is used to build large datasets that can train AI models.
Additionally, the company has developed an AI system called DeeImmuno. It is designed to predict whether a drug could be toxic and identify the biological reasons behind it. In internal testing on 100 drugs, the system identified different types of toxicity and their underlying mechanisms with a reported accuracy of 94 percent.
The focus on explaining why a drug is toxic, not just whether it is, reflects a broader shift in the industry. Regulators such as the U.S. Food and Drug Administration and the European Medicines Agency have been encouraging methods that rely more on human cell data and clearer biological evidence. The seed funding will be used to develop and scale these tools. The company aims to help drug developers make earlier decisions, which could reduce costly failures in later stages. Whether tools like this become widely used will depend on how they perform in real-world settings. For now, DeepCyte’s approach highlights a growing effort to make drug testing more precise by focusing on how drugs affect cells at the most detailed level.